Regulation of CD8 T cell responses to polyoma virus infection

CD8 T 细胞对多瘤病毒感染反应的调节

基本信息

  • 批准号:
    7546027
  • 负责人:
  • 金额:
    $ 5.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2009-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Persistent viral infections are a major cause of morbidity and mortality. Examples include HIV (resulting in AIDS), Cytomegalqvirus (CMV),. Epstein Barr virus (EBV) (responsible for mononucleosis, and; B cell lymphoma), Hepatitis C (leading to liver destruction), and Human Papiloma Virus (which may result in cervical cancer). Continual surveillance of CDS T cells is required to eliminate or, at minimum, control the spread of these viruses throughout the body. Understanding why CDS T cells are incapable of eliminating a persistent viral pathogen is a critical concern for human health. This proposal attempts to address key factors that may prove to be critical interventions to tilt the balance in favor of the host, allowing the elimination of the virus and the generation of a stable memory CDS T cell pool capable of preventing reinfection. The model for these studies is polyoma virus (PyV), a small, oncogenic DMA virus that infects mice (the natural host). CDS T cell immunity is critical to control tumor formation and outgrowth following infection, and a persistent viral infection can be detected in almost all tissues for life. The first aim of the proposal compares the evolution of PyV-specific T cells primed during acute and persistent phases of infection. These studies are performed using a novel recombinant PyV expressing OVA257-264 within the middle T antigen. Key differences may exist in the restrictions or conditions necessary for optimal priming at different time points, and this novel virus will allow us to clearly address this question using adoptive transfer of OT-I transgenic T cells at various time points post infection. Aim 2 addresses the role of dendritic cells in the priming of CDS T cells in persistent phase infection. Aim 3 involves the manipulation of costimulatory molecules (specifically CD27/CD70). This costimulatory molecule plays a critical role in the maintenance and development of memory CDS T cells. This subaim will also be investigated with adoptive transfer of OT- I transgenic T cells followed by treatment with soluble CD70 during persistent infection. Collectively, these studies should provide critical insights into possible therapeutic interventions to stimulate defective CDS T cell immunity observed in numerous persistent viral infections.
描述(由申请方提供):持续性病毒感染是发病和死亡的主要原因。实例包括HIV(导致AIDS)、巨细胞病毒(CMV)、.爱泼斯坦巴尔病毒(EBV)(导致单核细胞增多症和B细胞淋巴瘤)、丙型肝炎(导致肝脏破坏)和人乳头状瘤病毒(可能导致宫颈癌)。需要持续监测CDS T细胞,以消除或至少控制这些病毒在全身的传播。理解为什么CDS T细胞不能消除持久性病毒病原体是人类健康的关键问题。该提案试图解决可能被证明是关键干预措施的关键因素,以使平衡向有利于宿主的方向倾斜,从而消除病毒并产生能够防止再感染的稳定记忆CDS T细胞库。这些研究的模型是多瘤病毒(PyV),一种感染小鼠(天然宿主)的小型致癌DMA病毒。CDS T细胞免疫对于控制感染后的肿瘤形成和生长至关重要,并且几乎在所有组织中都可以检测到持续的病毒感染。该提案的第一个目的是比较在感染的急性和持续阶段引发的PyV特异性T细胞的演变。使用在中间T抗原内表达OVA 257 -264的新型重组PyV进行这些研究。关键差异可能存在于不同时间点的最佳引发所需的限制或条件中,并且这种新型病毒将允许我们在感染后的各个时间点使用OT-I转基因T细胞的过继转移来清楚地解决这个问题。目的2阐明树突状细胞在持续期感染中诱导CD 8 T细胞的作用。目的3涉及共刺激分子(特别是CD 27/CD 70)的操纵。这种共刺激分子在记忆CDS T细胞的维持和发育中起关键作用。该子目标还将用OT-1转基因T细胞的过继转移,随后在持续感染期间用可溶性CD 70处理来研究。总的来说,这些研究应该为可能的治疗干预提供重要的见解,以刺激在许多持续性病毒感染中观察到的缺陷CDS T细胞免疫。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER D PACK其他文献

CHRISTOPHER D PACK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER D PACK', 18)}}的其他基金

Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
个性化疫苗免疫疗法联合检查点抑制剂治疗三阴性乳腺癌的临床评价
  • 批准号:
    10551635
  • 财政年份:
    2022
  • 资助金额:
    $ 5.13万
  • 项目类别:
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
个性化疫苗免疫疗法联合检查点抑制剂治疗三阴性乳腺癌的临床评价
  • 批准号:
    10489848
  • 财政年份:
    2021
  • 资助金额:
    $ 5.13万
  • 项目类别:
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
个性化疫苗免疫疗法联合检查点抑制剂治疗三阴性乳腺癌的临床评价
  • 批准号:
    10687287
  • 财政年份:
    2021
  • 资助金额:
    $ 5.13万
  • 项目类别:
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
个性化疫苗免疫疗法联合检查点抑制剂治疗三阴性乳腺癌的临床评价
  • 批准号:
    10254572
  • 财政年份:
    2021
  • 资助金额:
    $ 5.13万
  • 项目类别:
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
基于膜的三阴性乳腺癌免疫疗法——一种合作方法
  • 批准号:
    9895637
  • 财政年份:
    2016
  • 资助金额:
    $ 5.13万
  • 项目类别:
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
基于膜的三阴性乳腺癌免疫疗法——一种合作方法
  • 批准号:
    10247102
  • 财政年份:
    2016
  • 资助金额:
    $ 5.13万
  • 项目类别:
A membrane-based immunotherapy for triple negative breast cancer
针对三阴性乳腺癌的基于膜的免疫疗法
  • 批准号:
    8524714
  • 财政年份:
    2013
  • 资助金额:
    $ 5.13万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 5.13万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了